Cassava Sciences, Inc. (SAVA)
| Market Cap | 1.68B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -60.59M |
| Shares Out | 40.10M |
| EPS (ttm) | -1.16 |
| PE Ratio | n/a |
| Forward PE | 39.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,039,321 |
| Open | 42.63 |
| Previous Close | 43.07 |
| Day's Range | 41.08 - 44.80 |
| 52-Week Range | 13.84 - 100.00 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 70.38 (+68.3%) |
| Earnings Date | Nov 8, 2022 |
About SAVA
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, T... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for SAVA stock is "Buy." The 12-month stock price forecast is 70.38, which is an increase of 68.29% from the latest price.
News
How High Can SAVA Stock Go Once the Controversy Clears?
Sometimes, it's hard to know who or what to believe. Such is the case when it comes to the ongoing U.S. Securities and Exchange Commission (SEC) probe into Cassava Sciences (NASDAQ: SAVA ).
Should you buy Cassava Sciences as the stock continue to soar
Retail interest in Cassava Sciences (NASDAQ:SAVA) remains far from over. The stock gained more than 6.7% on Wednesday, catapulting it to a 76% increase in value in a month.
Why Is Cassava Sciences (SAVA) Stock Heating Up Today?
Casava Sciences (NASDAQ: SAVA ) stock rose 5% overnight in sympathy with Biogen's (NASDAQ: BIIB ) successful clinical trial of an Alzheimer's drug called lecanemab. Lecanemab, developed with Eisai (OTCM...
5 Investors Betting Big on Cassava (SAVA) Stock
Shares of Cassava Sciences (NASDAQ: SAVA ) are down by over 15% following the previous day's gain of 35%. Yesterday, the Securities and Exchange Commission (SEC) announced that it had closed its case on...
The Huge Reason Cassava Sciences (SAVA) Stock Is Rocketing Higher
Deleted: Despite a significant down day for the S&P 500, shares of Cassava Sciences (NASDAQ: SAVA ) closed higher by 35%. That's because the Securities and Exchange Commission (SEC) has closed its case ...
Cassava Skyrockets After SEC Clears It Of Tampering With Alzheimer's Data
The SEC reportedly cleared an investigation into Cassava Sciences, leading SAVA stock to hit a seven-month high Thursday. The post Cassava Skyrockets After SEC Clears It Of Tampering With Alzheimer's Da...
What Is Going on With Cassava (SAVA) Stock Today?
Cassava Sciences (NASDAQ: SAVA ) stock rose nearly 30% on Sept. 20 as speculators bet on the company's efforts against Alzheimer's Disease.
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it has been invited t...
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
Cassava Sciences (NASDAQ: SAVA ) rose 9% overnight on reports director Richard Barry has invested $860,000 in the company's stock. The stock was due to open Aug. 26 at almost $30 per share, a market cap...
No Evidence of Data Manipulation in Science Publication on Simufilam
AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, was recently informed by the Journal of Pre...
Cassava Sciences, Blue Apron, and Revlon Stocks Exploded Out of the Gate Wednesday Morning
These vastly different companies have one thing in common.
Why Is Cassava Sciences (SAVA) Stock Up 20% Today?
Cassava Sciences (NASDAQ: SAVA ) rose 20% in overnight trading after board member Sanford Robertson bought 100,000 shares. Chief financial officer Eric Schoen also bought shares.
Stocks to watch: Apple, Digital World Acquistion Corp, Cassava Science, Canoo
Yahoo Finance Live host Seana Smith breaks down the action surrounding trending stocks in after-hours trading, including how the Trump-tied SPAC is filing to delay earnings.
Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of...
AUSTIN, Texas, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the s...
Cassava Sciences Responds to Media Reports
- In November 2021, Cassava Sciences previously disclosed that certain government agencies had asked for corporate information and at that time, the media widely reported on these prior disclosures.
Cassava (SAVA) Stock Falls 30% on Report of Criminal Probe
Cassava Biosciences (NASDAQ: SAVA ) stock is tumbling 30% in pre-market trading after Reuters reported today that the Justice Department has launched a criminal probe of the company. The news service ci...
US opens criminal probe into pharma company over potential Alzheimer's drug fraud: report
A Texas-based pharmaceutical company is facing a criminal probe into allegations that it manipulated data in its studies on its Alzheimer's drug simuflam on Wednesday.
Cassava's stock dives 24% after report citing alleged criminal probe of data from Alzheimer's drug trial
Shares of Cassava Sciences Inc. SAVA, +0.14% plunged 24.2% in premarket trading on Wednesday after Reuters reported that the Justice Department is investigating whether the company manipulated clinical ...
Exclusive-Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say
The U.S. Justice Department has opened a criminal investigation into Cassava Sciences Inc involving whether the biotech company manipulated research results for its experimental Alzheimer's drug, two pe...
7 Meme Stocks Trading at a Massive Discount Right Now
'Meme mania' has long since passed, but there may be an opportunity with these seven meme stocks trading at a discount right now. The post 7 Meme Stocks Trading at a Massive Discount Right Now appeared ...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Cassava Sciences, Inc.
Wilmington, Delaware--(Newsfile Corp. - July 7, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) on behalf of sto...
5 Short Squeeze Candidates To Watch This Week: 2 Former SPACs Join Leaderboard With BigBear.AI Topping List
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
NEW YORK , May 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to...
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 –